ExonHit Therapeutics is a biotechnology company that discovers and develops drugs based on its proprietary genomics technology known as DATAS(TM). The company focuses on neurodegenerative diseases, cancer and retinal disorders. The products under development include EHT 0202, EHT/AGN 0001, EHT 0101, EHT 0204 etc. ExonHit’s strategy is to leverage its IP by establishing partnerships in 3 major application areas – drug discovery, diagnostics and splice microarrays – in addition to developing its drug discovery program.